Dr Reddy’s gets two observations from USFDA for New York API plant
Dr Reddy’s Laboratories on Saturday (May 17, 2025) said the U.S. health regulator has issued a Form 483 with two observations after inspecting its U.S.-based facility. The U.S. Food and Drug Administration completed a Good Manufacturing Practice (GMP) inspection at the company’s API (active pharmaceutical ingredients) Middleburgh facility in New York, Dr Reddy’s said in […]
Continue Reading
